This summary is generated by an algorithm. If you find any mistakes, let us know.

Biotechnology Life Science North America Therapeutics

OnKure, Inc. Raises $55 Million Series B Financing

– OnKure, Inc. raised $55m in a Series B financing.
– Proceeds will be used to advance the Company’s next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.
– The financing was led by Acorn Bioventures with participation from additional new investors Cormorant Asset Management, Surveyor Capital (a Citadel company), Samsara BioCapital, Perceptive Advisors and funds and accounts managed by BlackRock.
– In connection with the financing, Isaac Manke, Ph.D., Partner at Acorn Bioventures, and Andrew Phillips, Ph.D., Managing Director at Cormorant Asset Management, will join the OnKure board of directors.

Source
Biopharma Biotechnology Health Care North America Therapeutics

Bionaut Labs Emerges From Stealth With $20M

– Bionaut Labs, a company focused on Revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut™ precision medicine treatment modality, today announced its launch backed by $20m financing led by Khosla Ventures.
– Other investors in the syndicate included Upfront Ventures, Revolution, BOLD Capital, and Compound.
– Proceeds from the financing support the advancement of the Company’s lead therapeutic program in glioma through preclinical development.

Source
Biopharma Biotechnology North America Therapeutics

Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop Groundbreaking New Technology Capable of Reversing Tissue and Organ Calcification

– Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.
– It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level.
– Elastrin’s lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification.
– The Elastrin team has developed a platform that can restore vascular health by removing pathological calcification specifically from sites where elastin has been degraded.

Source
Biopharma North America Pharmaceutical Therapeutics

BlossomHill Therapeutics Inks $71M Series A

– BlossomHill Therapeutics, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71m in a Series A financing round.
Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads.
– In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company’s Board of Directors.

Source
Biotechnology Developer Platform Medical North America Therapeutics

Amunix Pharmaceuticals Receives $117M

– Amunix Pharmaceuticals, a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, has raised $117m Series B financing.
– The funding round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management.

Source
Health Care Medical North America Therapeutics

Blue Note Therapeutics Raises $26.25 Million in Series A Financing

– Blue Note Therapeutics announced a $26.25m Series A financing round.
– The round was led by JAZZ Venture Partners and joined by Summer VC.
– Blue Note Therapeutics is dedicated to serving patients suffering from cancer-related distress.
– The capital will also support the development of Blue Note’s pipeline assets.

Source
Biotechnology Health Care North America Therapeutics

Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline

– Caribou Biosciences, Inc. announced the successful completion of an oversubscribed $115m Series C financing.
– Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.
– The Series C financing was co-led by new premier healthcare investors Farallon Capital Management, PFM Health Sciences, and Ridgeback Capital Investments.

Source
Biotechnology Health Care North America Therapeutics

Caribou Biosciences Raises $115M in Series C Funding

– Caribou Biosciences, Inc., a Berkeley, California-based clinical-stage CRISPR genome editing biotechnology company, raised $115m in Series C funding.
– The round was co-led by new premier healthcare investors Farallon Capital Management, PFM Health Sciences, and Ridgeback Capital Investments.

Source
Biotechnology Health Care Health Diagnostics North America Therapeutics

Century Therapeutics Closes $160M Series C Financing

– Century Therapeutics, a Philadelphia, PA-based cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, closed a $160m Series C financing.
– The round was led by Casdin Capital and brought together a syndicate of new investors including Fidelity Management & Research LLC, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital.
– Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.

Source
Health Diagnostics North America Pharmaceutical Therapeutics

Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology

– Janux Therapeutics announced the close of a $56m Series A financing.
– The financing was led by Avalon Ventures and joined by new investors, OrbiMed and RA Capital Management, as well as existing investors, Bregua and Correlation Ventures.
– In conjunction with the financing, Peter Thompson, M.D., partner at OrbiMed, and Jake Simson, Ph.D., partner at RA Capital Management, will join the Board of Directors.
– Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) technology is designed to overcome specific limitations of current T cell immuno-oncology therapies.

Source
1 2 3
Crunchbase icon

Content report

The following text will be sent to our editors: